William Blair Issues Positive Estimate for Exelixis Earnings

Exelixis, Inc. (NASDAQ:EXEL) – Research analysts at William Blair lifted their Q1 2025 earnings estimates for Exelixis in a report issued on Tuesday, February 11th. William Blair analyst A. Hsieh now expects that the biotechnology company will post earnings per share of $0.40 for the quarter, up from their prior forecast of $0.39. The consensus estimate for Exelixis’ current full-year earnings is $1.74 per share.

Other equities research analysts have also issued research reports about the stock. Barclays upped their target price on shares of Exelixis from $25.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday. Bank of America cut shares of Exelixis from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $35.00 to $39.00 in a research note on Tuesday, December 17th. Stifel Nicolaus raised their price objective on shares of Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a report on Wednesday. Citigroup boosted their target price on Exelixis from $38.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Wells Fargo & Company increased their price target on Exelixis from $32.00 to $36.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $37.24.

Exelixis Price Performance

Shares of NASDAQ:EXEL opened at $34.49 on Friday. The business’s fifty day moving average price is $34.21 and its two-hundred day moving average price is $30.75. Exelixis has a fifty-two week low of $20.14 and a fifty-two week high of $37.59. The stock has a market capitalization of $9.85 billion, a price-to-earnings ratio of 22.11, a price-to-earnings-growth ratio of 0.63 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 20.99% and a net margin of 22.43%.

Institutional Investors Weigh In On Exelixis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MetLife Investment Management LLC boosted its holdings in Exelixis by 8.1% during the fourth quarter. MetLife Investment Management LLC now owns 171,209 shares of the biotechnology company’s stock worth $5,701,000 after buying an additional 12,894 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new position in Exelixis during the 4th quarter worth approximately $158,000. Forum Financial Management LP acquired a new position in Exelixis during the fourth quarter valued at approximately $241,000. Alpha DNA Investment Management LLC bought a new stake in Exelixis in the fourth quarter valued at approximately $479,000. Finally, NewEdge Advisors LLC raised its holdings in Exelixis by 113.8% in the fourth quarter. NewEdge Advisors LLC now owns 27,908 shares of the biotechnology company’s stock worth $929,000 after purchasing an additional 14,857 shares during the period. Institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 10,000 shares of the company’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $35.27, for a total transaction of $352,700.00. Following the completion of the sale, the executive vice president now owns 278,665 shares in the company, valued at approximately $9,828,514.55. The trade was a 3.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the stock in a transaction on Friday, November 29th. The shares were sold at an average price of $36.67, for a total value of $2,200,200.00. Following the completion of the transaction, the executive vice president now directly owns 486,059 shares in the company, valued at approximately $17,823,783.53. This trade represents a 10.99 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 111,588 shares of company stock worth $3,981,864. Company insiders own 2.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.